A status report on the Pathway to Cures (P2C) portfolio of companies and founders we support through evergreen equity investing as of October 25, 2023.
Welcome to our first annual meeting of Pathway to Cures (P2C), the venture philanthropy fund of the National Bleeding Disorders Foundation.

November 1, 2023 marks the first year anniversary of the operating launch of the fund. A fund that was created to encourage early-stage biotechnology companies to consider bleeding disorders as important indications in clinical proof of principle and in doing so provide new solutions to address unmet needs in the community. We’re just getting started. Stay involved and watch us grow and the impact amplify.

$3.5 MM funds under management
114 companies reviewed
2 portfolio (investee) companies

$750 K invested
$12 MM raised by portfolio companies
2.5 FTE dedicated staff

*all numbers as of October 25, 2023
<table>
<thead>
<tr>
<th><strong>ANVESANA</strong></th>
<th><strong>FiveLiters</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>APPROACH:</strong> RNA-sequence target identification</td>
<td><strong>APPROACH:</strong> Non-invasive vagus nerve stimulation</td>
</tr>
<tr>
<td><strong>STRATEGIC AREA:</strong> ASO (Anti-sense Oligonucleotide) therapeutics for bleeding disorders</td>
<td><strong>STRATEGIC AREA:</strong> Non-invasive medical device</td>
</tr>
<tr>
<td><strong>P2C FUNDING IMPACT:</strong> Factor XI deficiency and women with Hemophilia</td>
<td><strong>P2C FUNDING IMPACT:</strong> Von Willebrand Disease and women with Heavy Menstrual Bleeding</td>
</tr>
<tr>
<td><strong>DATE OF INVESTMENT:</strong> September 2023</td>
<td><strong>DATE OF INVESTMENT:</strong> October 2023</td>
</tr>
</tbody>
</table>

**SCIENTIFIC ADVISORY GROUP**
Dr. Michael Recht, Chair; Dr. Katherine High; Dr. Hiang Jiang; Dr. Glenn Pierce, Co-Chair; Dr. Steven Pipe, Co-Chair; Dr. Len Valentino

**INVESTMENT COMMITTEE**
Brian Andrew, Chair; Dr. Christine Brennan; Dr. Geeta Vemuri; Teri Willey

**BOARD OF DIRECTORS**
Scott Martin, Chair; Dr. Amy Dunn; Dr. Len Valentino
Dr. Gilbert White, Vice Chair and Secretary

**DONOR ADVISORY COUNCIL**
Scott Martin

*Thank you to our founding donors -*
Scott & Kim Martin
Dr. Glenn Pierce
The Estate of Rebeca Ann Prather

Pathway to Cures (P2C), is an affiliate of the National Bleeding Disorders Foundation and is registered as a non-profit with 501(c)(3) status. As a venture philanthropy fund, neither management nor donors to P2C will receive capital distributions. Profits from investments made by P2C will be returned to the organization to further advance the mission.
**About Pathway to Cures**
Pathway to Cures (P2C) is a venture philanthropy fund created to accelerate development of cures across all inheritable blood and bleeding disorders. In collaboration with other organizations, P2C invests in innovative therapies and technologies, leveraging the deep resources and scientific community relationships of its parent organization, the National Bleeding Disorders Foundation. By reinvesting proceeds from investments back into the Fund, P2C will amplify investment impact, support promising companies, and build a portfolio of investments that further the mission of the National Bleeding Disorders Foundation.

**About National Bleeding Disorders Foundation**
The National Bleeding Disorders Foundation (formerly the National Hemophilia Foundation) is dedicated to finding cures for inheritable blood and bleeding disorders and to addressing and preventing the complications of these disorders through research, education, and advocacy enabling people and families to thrive. For more information, visit hemophilia.org.